Company intelligence

ELDN

Eledon Pharmaceuticals, Inc. · NASDAQ · Healthcare

Price$2.70-0.55% · −$0.02

Market cap208.02MEquity value

P / E-3.5Trailing ratio

Volume293.64KLatest session

Market data

ELDN price chart

TradingView

Related signals

1 min delayed

Browse public ELDN signals with their source context and measured market impact. Open any signal for its permanent analysis page.

ELDNNov 7, 2025+21.16% since signal

Eledon Pharmaceuticals' Lead Asset Fails In Mid-Stage Study, But Pushes Forward With Pivotal Study

Eledon stock down 59% after Phase 2 trial results. Tegoprubart showed higher eGFR but missed primary efficacy endpoints. The drug is moving to Phase 3 despite trial failures. Eledon has $93.4 million cash runway into late 2026. Phase 2 trial had significant patient volume, indicating strong interest.

View signal analysis

Research